Artificial organs最新文献

{"title":"Perfusion Pressures and Weight Loss During Normothermic Machine Perfusion of Human Donor Livers","authors":"Bianca Lascaris,&nbsp;Silke B. Bodewes,&nbsp;Adam M. Thorne,&nbsp;Marius C. van den Heuvel,&nbsp;Robbert J. de Haas,&nbsp;Maarten W. N. Nijsten,&nbsp;Vincent E. de Meijer,&nbsp;Robert J. Porte","doi":"10.1111/aor.14939","DOIUrl":"10.1111/aor.14939","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Normothermic machine perfusion (NMP) is increasingly used to preserve and assess donor livers prior to transplantation. Due to its success, it is expected that more centers will start using this technology. However, NMP may also cause adverse effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this retrospective, observational study, we investigated the effect of NMP pressures on donor liver weight, post-transplant outcomes, and hepatic perfusion characteristics. A total of 36 livers were transplanted after NMP. NMP perfusion pressure settings were lowered from a median (IQR) of 47 mmHg (42–54) to 34 mmHg (30–39) for the hepatic artery (HA), and from 8 mmHg (7–10) to 7 mmHg (6–8) for the portal vein (PV) to diminish potential edema formation inside the liver.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This change appeared to lead to a reduction of liver weight after NMP (−22 g to −143 g, <i>p</i> = 0.02), without affecting the PV flow velocity (35.5 to 48.0 cm/s, <i>p</i> = 0.54), or hepatocellular injury markers during NMP (AST 1511–1148 U/L, <i>p</i> = 0.44; ALT 318–849 U/L, <i>p</i> = 0.35), and post-transplantation outcomes. Changes in liver weight correlated significantly with the applied PV pressure during NMP (<i>r</i> = 0.52, <i>p</i> &lt; 0.01) and the HA flow (<i>r</i> = 0.38, <i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>NMP can lead to a reduction in liver weight, which might be masked by edema when high perfusion pressures are used. We encourage applying the lowest perfusion pressures possible to reach adequate flows and oxygen supply during liver NMP.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"49 5","pages":"820-830"},"PeriodicalIF":2.2,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.14939","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142906339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstracts from the IFESS 2024 conference","authors":"","doi":"10.1111/aor.14902","DOIUrl":"10.1111/aor.14902","url":null,"abstract":"","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"49 1","pages":"e1-e60"},"PeriodicalIF":2.2,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142906277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Cell-Based Extracorporeal Artificial Liver Systems: Historic Perspectives, Approaches and Mechanisms, Current Applications, and Challenges.","authors":"Alexander Novokhodko, Shaohang Hao, Suhail Ahmad, Dayong Gao","doi":"10.1111/aor.14931","DOIUrl":"https://doi.org/10.1111/aor.14931","url":null,"abstract":"<p><strong>Background: </strong>Liver disease is a growing burden. Transplant organs are scarce. Extracorporeal liver support systems (ELSS) are a bridge to transplantation for eligible patients. For transplant-ineligible patients the objective becomes liver recovery.</p><p><strong>Methods: </strong>We review seven decades of non-cell-based ELSS research in humans. Where possible, we emphasize randomized controlled trials (RCTs). When RCTs are not available, we describe the available human clinical data.</p><p><strong>Results: </strong>There are three broad cell-free approaches to remove protein-bound toxins (PBTs) and treat liver failure. The first is a dialysate binder suspension. A material that binds the PBT (the binder) is added to the dialysate. Binders include albumin, charcoal, and polystyrene sulfonate sodium. The unbound fraction of the PBT crosses the dialyzer membrane along a chemical gradient and binds to the binder. The second approach is using grains of sorbent fixed in a plastic housing to remove PBTs. Toxin-laden blood or plasma flows directly through the column. Toxins are removed by binding to the sorbent. The third approach is exchanging toxin-laden blood, or fractions of blood, for a healthy donor blood product. Most systems lack widespread acceptance, but plasma exchange (PE) is recommended in many guidelines. The large donor plasma requirement of PE creates demand for systems to complement or replace it.</p><p><strong>Conclusions: </strong>Now that PE has become recommended in some, but not all, jurisdictions, we discuss the importance of reporting precise PE protocols and dose. Our work provides an overview of promising new systems and lessons from old technologies to enable ELSS improvement.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142906332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrical stimulation and hybrid technologies-the International Functional Electrical Stimulation Society (IFESS) Conference 2024.","authors":"Tamsyn Street, Nathan Routledge, Leen Jabban, Benjamin Metcalfe, Ian Swain","doi":"10.1111/aor.14921","DOIUrl":"https://doi.org/10.1111/aor.14921","url":null,"abstract":"","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Machine Perfusion System for Enhancing Hepatic Microcirculation Perfusion","authors":"Lin Fan,&nbsp;Haoyang Xia,&nbsp;Guizhu Peng,&nbsp;Weiyu Wang,&nbsp;Zhen Fu,&nbsp;Qifa Ye","doi":"10.1111/aor.14930","DOIUrl":"10.1111/aor.14930","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Machine perfusion is a promising strategy for safeguarding liver transplants donated after cardiac death (DCD). In this study, we developed and validated a novel machine perfusion approach for mitigating risk factors and salvaging severe DCD livers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A novel hypothermic oxygenated perfusion (HOPE) system was developed, incorporating two pumps and an elastic water sac to emulate the functionality of the cardiac cycle. Compared to conventional systems (HOPE S1 and S2), the novel HOPE system (HOPE S3) was evaluated in rats, utilizing healthy livers perfused with methylene blue diluted using Histidine-tryptophan-ketoglutarate (HTK) solution or DCD livers subjected to 60 min of warm ischemia without heparin administration. Liver perfusion outcomes were assessed through macroscopic and microscopic evaluations, molecular analyses, and orthotopic liver transplantation (OLT).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>DCD livers subjected to HOPE systems' perfusion exhibited decreased injury and enhanced survival rates compared to static cold storage following 60 min of warm ischemia (DCD + SCS). The 4-week post-transplantation survival rates were 0%, 20%, and 33% in the DCD + SCS, HOPE S1, and HOPE S2 groups, respectively. HOPE S3 conferred protection against hepatocyte and non-parenchymal cell injury, resulting in a 67% animal survival rate following 60 min of warm donor ischemia (HOPE S3). Assessments of hepatic sinusoidal microcirculation, morphological changes, and molecular alterations in preserved livers further confirmed these findings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The newly devised machine perfusion system can enhance and uniform liver perfusion and may become a promising tool for revitalizing DCD liver grafts afflicted with severe warm ischemic injuries.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"49 4","pages":"582-591"},"PeriodicalIF":2.2,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience of Venoarterial Extracorporeal Life Support-Assisted Brain Death Donation With Severe Hemodynamic Instability","authors":"Yuling An,&nbsp;Pinglan Lu,&nbsp;Jianrong Liu,&nbsp;Shuai Huang,&nbsp;Xiaomeng Yi,&nbsp;Ziyu Li,&nbsp;Huimin Yi","doi":"10.1111/aor.14937","DOIUrl":"10.1111/aor.14937","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To explore the experience of extracorporeal life support (ECLS)-assisted maintenance of brain death donors with extremely unstable hemodynamics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed the clinical data of 12 brain-dead donors who received ECLS in our hospital from May 2015 to May 2022 due to extremely unstable hemodynamics. The organ acquisition status was analyzed. The transplant outcome of the livers and kidneys procured from these donors on ECLS was also evaluated, who are currently considered as having extended criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After ECLS, the hemodynamics of these 12 patients quickly stabilized and all completed apnea testing and reached the criteria for brain death. The 12 donors on ECLS contributed 36 organs: 1 heart, 2 lungs, 11 livers, and 22 kidneys. All liver and kidney transplant recipients survived within 1 year after transplantation. The 12-month graft survival rate for these 22 ECLS transplanted kidneys was 95%. Four (18.2%) kidney transplant recipients developed DGF. The average creatinine at discharge was 2.01 ± 0.70 mg/dL (1.14–3.67 mg/dL), which showed a downward trend in the first year after operation. The 12-month graft survival rate for these 11 ECLS transplanted livers was 100%. There was no incidence of primary nonfunction. The transaminase and bilirubin in the liver transplantation recipient group showed a downward trend, with an average total bilirubin of 2.23 ± 0.17 mg/dL (1.93–2.46 mg/dL) and an average alanine aminotransferase level of 46.55 ± 17.45 (33–89 units/L) at the time of discharge.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>ECLS can maintain the organ function of potential brain death donors with extremely unstable circulation and does not affect the functional recovery of the graft.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"49 5","pages":"880-885"},"PeriodicalIF":2.2,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142891497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consumer views of functional electrical stimulation and robotic exoskeleton in SCI rehabilitation: A mini review","authors":"Yalian Pei,&nbsp;Mari Tobita,&nbsp;Benjamin Dirlikov,&nbsp;Dannae Arnold,&nbsp;Candace Tefertiller,&nbsp;Ashraf Gorgey","doi":"10.1111/aor.14925","DOIUrl":"10.1111/aor.14925","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Functional electrical stimulation (FES) and robotic exoskeletons represent emerging technologies with significant potential for restoring critical physical functions such as standing and walking—functions that are most susceptible after spinal cord injury (SCI). However, the further development and successful integration of these technologies into clinical practice and daily life require a deep understanding of consumer perspectives.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This review synthesizes consumer perspectives from a diverse range of technology stakeholders, including medical service providers, researchers, and persons affected by SCI—those living with SCI and their caregivers. By capturing this diverse range of perspectives, the review aims to describe the real-world implications, challenges, and expectations associated with FES and robotic exoskeleton technologies.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Relevant literature was primarily identified through a search in EBSCO, SCOPUS, and Web of Science. The authors supplemented the search by reviewing reference lists including appropriate articles identified by the authors. The PICO question guiding this process was defined as P (persons with SCI and caregivers, researchers, clinicians, and developers), I (use of FES or robotic exoskeletons), C (technology users compared to non-users), and O (stakeholder perspectives and experiences). Each identified article underwent a thorough appraisal, after which findings were summarized to present consumers' viewpoints on FES and robotic exoskeleton technologies.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The review focuses on key areas such as perceived benefits, limitations, implementation barriers, and consumer expectations. The benefits identified are multifaceted, extending from physical improvements, such as enhanced mobility and muscle strength, to psychological gains including increased confidence and sense of independence. However, these technologies also face perceived limitations, often related to accessibility, cost, and usability challenges. Beyond technical issues, implementation barriers are related to factors like insurance coverage and the need for specialized training for both users and providers. Consumer expectations include hope for technological advancements, increased accessibility and affordability, and a desire for more personalized and adaptable solutions tailored to the unique needs of individuals with SCI.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;secti","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"49 5","pages":"729-748"},"PeriodicalIF":2.2,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.14925","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142875990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Albumin Administration in Veno-Arterial Extracorporeal Membrane Oxygenation","authors":"Tobias Wengenmayer,&nbsp;Marvin L. Hirth,&nbsp;Markus Jäckel,&nbsp;Xavier Bemtgen,&nbsp;Klaus Kaier,&nbsp;Paul M. Biever,&nbsp;Alexander Supady,&nbsp;Thomas Maulhardt,&nbsp;Dirk Westermann,&nbsp;Dawid L. Staudacher,&nbsp;Jonathan Rilinger","doi":"10.1111/aor.14934","DOIUrl":"10.1111/aor.14934","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The clinical outcome and fluid balance of patients with veno-arterial extracorporeal membrane oxygenation (VA ECMO) or after extracorporeal cardiopulmonary resuscitation (eCPR) may be improved by addressing the high fluid demand with an early albumin administration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective observational study, patients supported with VA ECMO or eCPR received early albumin administration (25 g/L) to prime the VA ECMO system. These patients were compared to patients who received a regimen based solely on balanced crystalloids (crystalloid group) or a regimen based on a 1:4 volume mixture of albumin (10 g/L) and balanced crystalloids (albumin group).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>660 VA ECMO patients (66.4% eCPR) treated between January 2017 and June 2021 were analyzed, whereby 265 patients received crystalloid fluid therapy, 269 patients received albumin therapy, and 126 patients received early albumin therapy.</p>\u0000 \u0000 <p>When compared to the albumin and crystalloid groups, patients in the early albumin treatment group had significantly lower cumulative fluid balances (<i>p</i> &lt; 0.05). However, this effect was only observed in the group of eCPR patients and not in patients with cardiogenic shock. Logistic regression revealed albumin administration as an independent predictor of increased survival (Odds ratio 1.66 (1.11–2.47) [95%-CI], <i>p</i> = 0.013). Yet, only eCPR patients showed a survival benefit from albumin administration compared to the crystalloid group (survival of 29.4% vs. 18.8%, <i>p</i> = 0.024).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Early albumin administration in eCPR patients was linked to a significant decline in fluid balance. Moreover, volume therapy with albumin application was an independent predictor for improved survival in eCPR patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"49 5","pages":"872-879"},"PeriodicalIF":2.2,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.14934","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142875994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Membrane Designed Polyether Sulfone Filter Reduces Filtration Membrane Obstruction Rate in Drop-Type With Adjustable Concentrator Cell-Free and Concentrated Ascites Reinfusion Therapy (DC-CART)","authors":"Keita Inui,&nbsp;Yosuke Yamada,&nbsp;Daiki Aomura,&nbsp;Kosuke Sonoda,&nbsp;Makoto Harada,&nbsp;Koji Hashimoto,&nbsp;Yuji Kamijo","doi":"10.1111/aor.14932","DOIUrl":"10.1111/aor.14932","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In cell-free and concentrated ascites reinfusion therapy (CART), filtration membrane obstruction during the ascites processing step is an important clinical problem. A novel membrane designed polyether sulfone filter (n-PES) was developed to reduce filter membrane obstruction. However, no clinical studies have compared the performance of n-PES filters with that of conventional filters. Therefore, we aimed to assess whether n-PES filters reduce membrane obstruction compared to conventional polyethylene (PE) filters during CART ascites processing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a single-center, retrospective, observational, controlled cohort study. We compared ascites processing records from the drop-type with adjustable concentrator CART (DC-CART) sessions that used n-PES filters with those that used conventional PE filters. The primary outcome was the occurrence rate of membrane obstruction. Propensity score matching was used to assemble DC-CART sessions with comparable baseline ascites characteristics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 173 DC-CART sessions, 31 sessions using n-PES filters and 31 using PE filters with similar propensity scores were included in the analysis. The rate of filter membrane obstruction was significantly lower in the n-PES group than in the PE group (<i>p</i> = 0.049). Additionally, the total treatment time was significantly shorter for the n-PES group (<i>p</i> = 0.006). No sessions experienced issues with the processing procedure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This is the first study to demonstrate that an n-PES filter reduces the incidence of filter membrane obstruction in clinical CART sessions using human ascites. The n-PES filter may reduce the burden on the medical staff performing CART.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"49 4","pages":"592-599"},"PeriodicalIF":2.2,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.14932","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two Coupled Continuous-Flow Ventricular Assist Devices as a Novel BIVAD With One Driveline: Acute Animal Study Results","authors":"Sara Knigge,&nbsp;Günes Dogan,&nbsp;Ezin Deniz,&nbsp;Jasmin Hanke,&nbsp;Ali Merzah,&nbsp;Dominik Berliner,&nbsp;Fanwu Kong,&nbsp;Torsten Heilmann,&nbsp;Bastian Schmack,&nbsp;Aron F. Popov,&nbsp;Alexander Weymann,&nbsp;Johann Bauersachs,&nbsp;Arjang Ruhparwar,&nbsp;Jan D. Schmitto","doi":"10.1111/aor.14933","DOIUrl":"10.1111/aor.14933","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The study assesses the feasibility of the DuoCor BiVAS, a novel biventricular assist system integrating magnetic levitation technology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In an acute large animal model involving five sheep, each received the DuoCor BiVAS without cardiopulmonary bypass. Hemodynamic and device parameters were monitored continuously for 1-h post-implantation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Intraoperative implantation was uneventful, demonstrating successful biventricular support with mean blood flows of 5.4 LPM (left) and 5.5 LPM (right). Analysis showed proportional flow rates and relationships between pump speed, flow, and power consumption. No adverse events like thrombus formation, bleeding, stroke, or device failure occurred.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This research underscores the DuoCor BiVAS's potential for severe biventricular heart failure treatment, providing insights into its feasibility and functionality in acute animal models. The findings suggest promising clinical applications, particularly with the system's single driveline design potentially enhancing patient mobilization and quality of life. Further investigations are needed to advance this technology for broader clinical use.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"49 3","pages":"525-531"},"PeriodicalIF":2.2,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.14933","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}